ScinoPharm Taiwan, Ltd. (TPE:1789)

Market Cap	15.06B
Revenue (ttm)	3.21B
Net Income (ttm)	245.35M
Shares Out	790.74M
EPS (ttm)	0.31
PE Ratio	61.19
Forward PE	n/a
Dividend	0.35 (1.84%)
Ex-Dividend Date	Jul 4, 2024

Volume	248,410
Average Volume	387,678
Open	19.10
Previous Close	19.20
Day's Range	18.80 - 19.10
52-Week Range	16.50 - 30.50
Beta	0.36
RSI	46.44
Earnings Date	May 5, 2025

About ScinoPharm Taiwan

ScinoPharm Taiwan, Ltd., together with its subsidiaries, research and develops, produces, and sells active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, rest of Asia, Europe, India, the United States and internationally. The company provides small molecular drugs, protein drugs, complex natural molecules and derivatives, synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; outsourcing services. It offers CRAM services, such as chemistry skill, analytical...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 540
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1789

Financial Performance

In 2024, ScinoPharm Taiwan's revenue was 3.41 billion, an increase of 6.91% compared to the previous year's 3.19 billion. Earnings were 339.35 million, an increase of 18.22%.